Please use this identifier to cite or link to this item: https://hdl.handle.net/10316/113961
Title: Circulating Dopamine Is Regulated by Dietary Glucose and Controls Glucagon-like 1 Peptide Action in White Adipose Tissue
Authors: Tavares, Gabriela 
Rosendo-Silva, Daniela 
Simões, Flávia Viegas 
Eickhoff, Hans 
Marques, Daniela 
Sacramento, Joana F.
Capucho, Adriana M.
Seiça, Raquel 
Conde, Sílvia V. 
Matafome, Paulo 
Keywords: dopamine; GLP-1; white adipose tissue
Issue Date: 27-Jan-2023
Publisher: MDPI
Project: UID/NEU/04539/2013 
UID/NEU/04539/2019 
UIDB/04539/2020 
info:eu-repo/grantAgreement/UIDP/04539/2020 
PD/BD/127822/2016 
2021.08160.BD 
CEEC IND/02428/2018 
Serial title, monograph or event: International Journal of Molecular Sciences
Volume: 24
Issue: 3
Abstract: Dopamine directly acts in the liver and white adipose tissue (WAT) to regulate insulin signaling, glucose uptake, and catabolic activity. Given that dopamine is secreted by the gut and regulates insulin secretion in the pancreas, we aimed to determine its regulation by nutritional cues and its role in regulating glucagon-like peptide 1 (GLP-1) action in WAT. Solutions with different nutrients were administered to Wistar rats and postprandial dopamine levels showed elevations following a mixed meal and glucose intake. In high-fat diet-fed diabetic Goto-Kakizaki rats, sleeve gastrectomy upregulated dopaminergic machinery, showing the role of the gut in dopamine signaling in WAT. Bromocriptine treatment in the same model increased GLP-1R in WAT, showing the role of dopamine in regulating GLP-1R. By contrast, treatment with the GLP-1 receptor agonist Liraglutide had no impact on dopamine receptors. GLP-1 and dopamine crosstalk was shown in rat WAT explants, since dopamine upregulated GLP-1-induced AMPK activity in mesenteric WAT in the presence of the D2R and D3R inhibitor Domperidone. In human WAT, dopamine receptor 1 (D1DR) and GLP-1R expression were correlated. Our results point out a dietary and gut regulation of plasma dopamine, acting in the WAT to regulate GLP-1 action. Together with the known dopamine action in the pancreas, such results may identify new therapeutic opportunities to improve metabolic control in metabolic disorders.
URI: https://hdl.handle.net/10316/113961
ISSN: 1422-0067
DOI: 10.3390/ijms24032464
Rights: openAccess
Appears in Collections:I&D CIBB - Artigos em Revistas Internacionais
FMUC Medicina - Artigos em Revistas Internacionais
I&D ICBR - Artigos em Revistas Internacionais

Show full item record

Google ScholarTM

Check

Altmetric

Altmetric


This item is licensed under a Creative Commons License Creative Commons